13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuropharmacologists
Neuropharmacologists examine how drugs interact with the nervous system, focusing on their effects on receptors, neurotransmitters, and enzymes in the brain. Their work is crucial in developing treatments for neurological disorders such as depression, anxiety, schizophrenia, and Parkinson’s disease. By understanding the pharmacodynamics of drugs—how they affect brain function—neuropharmacologists explore ways to enhance or inhibit specific neurochemical pathways to treat these conditions. Additionally, they study pharmacokinetics, which involves understanding how drugs are absorbed, metabolized, and eliminated by the body, to optimize drug dosages and reduce side effects. Neuropharmacologists are instrumental in advancing drug development, identifying new therapeutic targets, and designing medications with improved efficacy and fewer adverse reactions. Their expertise extends into addiction medicine, as they investigate how substances of abuse impact the brain and contribute to dependence and withdrawal symptoms. By conducting rigorous clinical trials, neuropharmacologists assess the safety and effectiveness of new medications, ensuring that patients receive the best possible treatments tailored to their needs.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States